GERMANTOWN, Maryland, and HILDEN, Germany, September 8, 2016 /PRNewswire/ --
U.S. Preventive Services Task Force issues recommendations to screen high-risk patients
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today welcomed recommendations issued by the U.S. Preventive Services Task Force (USPSTF) that primary care clinicians screen adult patients in groups at high risk for latent tuberculosis infection (LTBI), a condition that produces no symptoms but can progress to active tuberculosis, a highly contagious and potentially fatal disease. The final USPSTF recommendations refer to QIAGEN's QuantiFERON-TB® Gold (QFT®) as a test proven to be reliable in screening for latent TB infection and suggest that this class of test may be preferable in certain patient groups.
"The Task Force acknowledges tuberculosis as 'an important, preventable disease' in the United States and the new LTBI guidelines are unprecedented in that it expands the scope of testing to all providers, and calls upon primary care physicians to play a key role in ending tuberculosis in the United States." said Dr. Masae Kawamura, Senior Director of Medical and Scientific Affairs for QIAGEN. "Up to now, TB screening in the United States and most countries has been limited to public health programs, specialty physicians, and facilities under health regulations. The new directive of the USPSTF LTBI guidelines for primary care clinicians is truly an important step to eliminate tuberculosis in the US."
Click here for full press release
Contacts:
Public Relations:
Dr. Thomas Theuringer
Senior Director Public Relations
+49-2103-29-11826
Email: pr@qiagen.com
http://www.twitter.com/qiagen
https://www.facebook.com/QIAGEN
pr.qiagen.com
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
Email: ir@qiagen.com
ir.qiagen.com
SOURCE QIAGEN N.V.
